SIDEBAR: Oncology Drug Approvals in 2014

By The ASCO Post Staff
March 15, 2014

February 12, 2014: Ibrutinib (Imbruvica) receives accelerated approval for patients with chronic lymphocytic leukemia who have received at least one prior therapy.

January 10, 2014: Trametinib (Mekinist) and dabrafenib (Tafinlar) receive approval for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Omacetaxine Mepesuccinate Receives Full FDA Approval for CML

The U.S. Food and Drug Administration (FDA) has granted full approval to omacetaxine mepesuccinate (Synribo) for injection. The full approval was based on the final analysis of two phase II trials that evaluated the efficacy and tolerability data of omacetaxine. The agent received an accelerated...

Apr

Today In Oncology

SIDEBAR: Oncology Drug Approvals in 2014

Related Articles

Omacetaxine Mepesuccinate Receives Full FDA Approval for CML

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer